While glucose-stimulated insulin secretion and GLP-1 release are severely impaired in T2D [13], [14], the fatty acid receptors, a group of G-protein coupled receptors, such as GPR40 and GPR120 that are activated by medium- and long-chain FFAs, have been suggested as potential drug targets for T2D [15]. The gene discussed is FFAR1; the disease is type 2 diabetes mellitus.